Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1292263 co-administered with metformin in Type 2 Diabetes
NCT01128621Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GSK-1292263 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by GSK. Primary endpoints: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Abnormal Hematology Values of Potential Clinical Importance (PCI) and 22 more. Started Nov 2009; status: completed.
02
Drugs
GSK-1292263
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01128621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01128621.